JP4444372B2 - 診断、予防および治療のための多発性硬化症に関与するウイルス性物質およびヌクレオチドフラグメント - Google Patents

診断、予防および治療のための多発性硬化症に関与するウイルス性物質およびヌクレオチドフラグメント Download PDF

Info

Publication number
JP4444372B2
JP4444372B2 JP50817997A JP50817997A JP4444372B2 JP 4444372 B2 JP4444372 B2 JP 4444372B2 JP 50817997 A JP50817997 A JP 50817997A JP 50817997 A JP50817997 A JP 50817997A JP 4444372 B2 JP4444372 B2 JP 4444372B2
Authority
JP
Japan
Prior art keywords
sequence
seq
msrv
nucleic acid
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP50817997A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11502416A (ja
JPH11502416A5 (enExample
Inventor
エルベ ペロン，
フレデリク ベゼム，
フレデリク ベダン，
グローシア パラノース−バカラ，
フローレンス コムリアン−プラデル，
コレット ジョリーヴェ−レイノー，
ベルナール マンドラン，
Original Assignee
ベーイーオー・メリュー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーイーオー・メリュー filed Critical ベーイーオー・メリュー
Publication of JPH11502416A publication Critical patent/JPH11502416A/ja
Publication of JPH11502416A5 publication Critical patent/JPH11502416A5/ja
Application granted granted Critical
Publication of JP4444372B2 publication Critical patent/JP4444372B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
JP50817997A 1995-08-03 1996-08-02 診断、予防および治療のための多発性硬化症に関与するウイルス性物質およびヌクレオチドフラグメント Expired - Lifetime JP4444372B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9509643A FR2737500B1 (fr) 1995-08-03 1995-08-03 Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
FR95/09643 1995-08-03
PCT/FR1996/001244 WO1997006260A1 (fr) 1995-08-03 1996-08-02 Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009265658A Division JP5143814B2 (ja) 1995-08-03 2009-11-20 診断、予防および治療のための多発性硬化症に関与するウイルス性物質およびヌクレオチドフラグメント

Publications (3)

Publication Number Publication Date
JPH11502416A JPH11502416A (ja) 1999-03-02
JPH11502416A5 JPH11502416A5 (enExample) 2004-07-15
JP4444372B2 true JP4444372B2 (ja) 2010-03-31

Family

ID=9481811

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50817997A Expired - Lifetime JP4444372B2 (ja) 1995-08-03 1996-08-02 診断、予防および治療のための多発性硬化症に関与するウイルス性物質およびヌクレオチドフラグメント
JP2009265658A Expired - Lifetime JP5143814B2 (ja) 1995-08-03 2009-11-20 診断、予防および治療のための多発性硬化症に関与するウイルス性物質およびヌクレオチドフラグメント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009265658A Expired - Lifetime JP5143814B2 (ja) 1995-08-03 2009-11-20 診断、予防および治療のための多発性硬化症に関与するウイルス性物質およびヌクレオチドフラグメント

Country Status (19)

Country Link
US (4) US6001987A (enExample)
EP (2) EP0789077B1 (enExample)
JP (2) JP4444372B2 (enExample)
AT (2) ATE374252T1 (enExample)
AU (1) AU730080B2 (enExample)
BG (1) BG62977B1 (enExample)
BR (1) BR9606566A (enExample)
CA (1) CA2201282C (enExample)
CZ (1) CZ135797A3 (enExample)
DE (1) DE69637264T2 (enExample)
ES (2) ES2293645T3 (enExample)
FR (1) FR2737500B1 (enExample)
HU (1) HUP9900425A3 (enExample)
IS (1) IS4455A (enExample)
NO (1) NO971493L (enExample)
NZ (1) NZ316080A (enExample)
PL (1) PL319512A1 (enExample)
SK (1) SK56797A3 (enExample)
WO (1) WO1997006260A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2737500B1 (fr) * 1995-08-03 1997-08-29 Bio Merieux Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
ES2347854T5 (es) * 1996-03-26 2014-07-24 Michael S. Kopreski Método que permite el uso de RNA extracelular extraído de plasma o suero para detectar, monitorizar o evaluar un cáncer
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
US6344317B2 (en) * 1996-10-04 2002-02-05 Chronix Biomedical, Inc. Diagnostic detection of nucleic acids
CA2272845C (en) 1996-11-26 2010-01-12 Bio Merieux Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
FR2762600B1 (fr) * 1997-04-29 1999-11-05 Bio Merieux Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utlisations
FR2762601B3 (fr) * 1997-04-29 1999-06-04 Bio Merieux Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utilisations
ATE346153T1 (de) * 1997-07-07 2006-12-15 Bio Merieux Endogene retrovirale sequenzen, verwandten mit auto-immune krankheiten oder mit schwangerschaftsstörungen
FR2765588A1 (fr) * 1997-07-07 1999-01-08 Bio Merieux Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques
US20040176314A1 (en) * 1997-07-07 2004-09-09 Bio Merieux Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders
WO1999053103A1 (en) * 1998-04-08 1999-10-21 Ms Research A/S Diagnosis of multiple sclerosis and other demyelinating diseases
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
US20090233276A1 (en) * 1998-09-22 2009-09-17 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
FR2788784A1 (fr) 1999-01-21 2000-07-28 Bio Merieux Fragment nucleique endogene associe a une maladie auto-immune, procede de marquage et reactif
EP1029917A1 (en) * 1999-02-15 2000-08-23 Bio Merieux The LTR region of MSRV-1 and the proteins it encodes, and probes and methods for detecting MSRV-1 retrovirus
AU6785700A (en) * 1999-08-20 2001-03-19 Biogen, Inc. Novel polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby
DE10012875B4 (de) * 2000-03-16 2004-04-01 Infineon Technologies Ag Mobilfunkempfänger
JP2004502407A (ja) * 2000-03-21 2004-01-29 エムエス　リサーチ　アクティー　ゼルスカブ 感染性内在性レトロウイルスならびにその脱髄疾患および他の疾患との関係
ATE502119T1 (de) * 2001-07-25 2011-04-15 Oncomedx Inc Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
US8680065B2 (en) * 2008-09-11 2014-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oligonucleotides of human endogenous retrovirus 9 (ERV-9) long terminal repeat (LTR) and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980000412A1 (en) * 1978-08-24 1980-03-20 N Gilmour Pasteurellosis vaccines
US4311686A (en) * 1979-04-30 1982-01-19 The Immunology Development Corporation Methodology for the immunodiagnosis of multiple sclerosis and/or malignant diseases from blood sample analysis
US4396600A (en) * 1980-12-18 1983-08-02 Gus Gallucci Adult schistosome worm-derived antigenic substance and method of obtaining same
US4388298A (en) * 1982-07-14 1983-06-14 The United States Of America As Represented By The Secretary Of Agriculture Propagation of hemorrhagic enteritis virus in a turkey cell line and vaccine produced
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
US4647773A (en) * 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
NZ218050A (en) * 1985-11-13 1989-05-29 Wistar Inst Test for the presence of htlv-1v
US4900553A (en) * 1987-09-11 1990-02-13 Case Western Reserve University Method of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
EP0326395A2 (en) * 1988-01-29 1989-08-02 City Of Hope Method of detecting and identifying certain viral sequences
FR2651581B1 (fr) * 1989-09-06 1994-05-13 Centre Nal Recherc Scientifique Moyens pour le diagnostic de neuropathies demyelinisantes, en particulier de la sclerose en plaques.
US5219837A (en) * 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5158976A (en) * 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
AU672359B2 (en) * 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
DK173091D0 (da) * 1991-10-11 1991-10-11 Schleroseforeningen The Danish Biologisk materiale
FR2689520B1 (fr) 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
FR2689521B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
DE69333950T2 (de) * 1992-05-18 2006-08-17 Genentech, Inc., South San Francisco Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden
GB9310657D0 (en) * 1993-05-24 1993-07-07 Univ London Retrovirus
US5580766A (en) * 1994-01-14 1996-12-03 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
ES2233936T3 (es) * 1994-02-04 2005-06-16 Bio Merieux Virus msrv1 asociado a la esclerosis en placas, sus constituyentes nucleicos y sus aplicaciones.
US5691147A (en) * 1994-06-02 1997-11-25 Mitotix, Inc. CDK4 binding assay
US5710037A (en) * 1994-06-10 1998-01-20 The United States Of America As Represented By The Department Of Health And Human Services Retroviral vector particles
FR2731356B1 (fr) * 1995-03-09 1997-04-30 Bio Merieux Virus msrv-1 et agent pathogene et/ou infectant msrv-2 associes a la polyarthrite rhumatoide
FR2737500B1 (fr) * 1995-08-03 1997-08-29 Bio Merieux Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques

Also Published As

Publication number Publication date
AU6823296A (en) 1997-03-05
CA2201282C (fr) 2013-04-02
CA2201282A1 (fr) 1997-02-20
ES2379011T3 (es) 2012-04-19
US6579526B1 (en) 2003-06-17
US20070117189A1 (en) 2007-05-24
AU730080B2 (en) 2001-02-22
JPH11502416A (ja) 1999-03-02
ATE374252T1 (de) 2007-10-15
US7932350B2 (en) 2011-04-26
US20030186391A1 (en) 2003-10-02
EP1916304A2 (fr) 2008-04-30
IS4455A (is) 1997-03-26
EP0789077A1 (fr) 1997-08-13
CZ135797A3 (cs) 1998-06-17
SK56797A3 (en) 1998-09-09
WO1997006260A1 (fr) 1997-02-20
DE69637264D1 (de) 2007-11-08
NO971493L (no) 1997-06-03
EP1916304B1 (fr) 2012-01-18
BR9606566A (pt) 1997-12-30
EP0789077B1 (fr) 2007-09-26
NO971493D0 (no) 1997-04-02
FR2737500B1 (fr) 1997-08-29
HUP9900425A2 (hu) 1999-05-28
EP1916304A3 (fr) 2008-05-07
NZ316080A (en) 1999-04-29
ATE541933T1 (de) 2012-02-15
DE69637264T2 (de) 2008-06-26
US6001987A (en) 1999-12-14
HUP9900425A3 (en) 1999-11-29
PL319512A1 (en) 1997-08-18
FR2737500A1 (fr) 1997-02-07
BG62977B1 (bg) 2000-12-29
JP5143814B2 (ja) 2013-02-13
BG101355A (en) 1997-12-30
ES2293645T3 (es) 2008-03-16
JP2010047604A (ja) 2010-03-04

Similar Documents

Publication Publication Date Title
JP4444372B2 (ja) 診断、予防および治療のための多発性硬化症に関与するウイルス性物質およびヌクレオチドフラグメント
JP3611856B2 (ja) 多発性硬化症に関与するｍｓｒｖ１ウイルスおよびｍｓｒｖ２病因性及び／又は感染性の作因、核酸成分およびその応用
JP4226657B2 (ja) 診断、予防、及び治療のための、多発性硬化症に関連するウイルス性物質及びヌクレオチド断片
US5798205A (en) Retrovirus from the HIV type O and its use (MVP-2901/94)
US6548635B1 (en) Retrovirus from the HIV type O and its use (MVP-2901/94)
JP4249269B2 (ja) 自己免疫疾患および／または妊娠障害に関連する内因性レトロウイルス配列
US8088910B2 (en) Isolated multiple sclerosis (MS)-associated retrovirus (MSRV) nucleic acids corresponding to the gag region
CZ328796A3 (en) Msrv-1 virus and pathogenic and/or infection inducing msrv-2 factor being connected with rheumatic arthritis

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060201

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070301

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20070405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091120

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100114

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130122

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term